Inhabitation of type insulin-like growth factor receptor stimulates apoptosis induced by anticancer drugs in a human neurobustoma cell live without N-mycamplitication

类胰岛素生长因子受体的抑制刺激抗癌药物诱导的无 N-mycampliitation 的人神经母细胞瘤细胞凋亡

• 批准号: 13671866
• 负责人: WASA Masafumi
• 金额: $ 0.7万
• 依托单位: Osaka University
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Scientific Research (C)
• 财政年份: 2001
• 资助国家: 日本
• 起止时间: 2001 至 2002
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-13671866/
• 关键词: Neuroblastoma; N-myc; IGF-1 receptor; 癌増殖

We investigated whether the blockage of IGF-I receptor (IGE-IR) by a monoclonal antibody against IGF-IR (αIR3) may be advantageously combined with conventional cytotoxic drugs for the design of more effective therapeutic regimens. Here, we used the well-characterized neuroblastoma cell line, SK-N-SH, that is known to express low level of N-myc amplification. Our findings indicate that combined treatment using αIR3 with cisplatin and doxorubicin significantly enhance in vitro cytotoxic effects of chemotherapeutic drugs by stimulating apoptotic process. Therapies that target the IGF-IR combined with traditional anticancer drugs should improve the effectiveness of the chemotherapy and probably even allow the usage of considerably lower doses of toxic drugs.

我们研究了抗IGF-IR单克隆抗体（αIR3）阻断IGF-I受体（IGE-IR）是否可以与传统的细胞毒性药物联合使用，以设计更有效的治疗方案。在这里，我们使用了具有良好特征的神经母细胞瘤细胞系SK-N-SH，已知其表达低水平的N-myc扩增。我们的研究结果表明，αIR3与顺铂和阿霉素联合治疗通过刺激细胞凋亡过程显著增强化疗药物的体外细胞毒作用。以IGF-IR为目标的治疗方法与传统的抗癌药物相结合，应该会提高化疗的效果，甚至可能允许使用相当低剂量的有毒药物。

项目成果

M.Wasa, HS.Wang, A.Okada: "Characterization of L-glutamine transport by a human neuroblastoma cell line"Am. J. Physiol-Cell Physiol. (in press).

M.Wasa、HS.Wang、A.Okada：“人神经母细胞瘤细胞系 L-谷氨酰胺转运的表征”Am。

Wasa M, Wang HS, Okada A: "Characterization of L-glutamine transport by a human neuroblastoma cell line"Am J Physiol -Cell Physiol. 282(6). 1246-1253 (2002)

Wasa M、Wang HS、Okada A：“人神经母细胞瘤细胞系 L-谷氨酰胺转运的表征”Am J Physiol -Cell Physiol。